MalarVx
Seattle, US · Founded 2012 · Washington corporation
A company focused on addressing malaria through research and solutions aimed at reducing the disease's health and economic burden.
Founders & leadership
JH
Jodi HerczegExecutive
JW
James Wayne DavieNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.2M disclosed across 2 of 3 rounds · 2015–2026
▶$125KraisedAug 2026 · 2 investors · BiotechnologyRule 506(b)
▶$125KraisedAug 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James DavieDirector
- Jodi HerczegExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $125K
- Minimum investment
- $25K
- Proceeds to insiders
- $50K
- First sale
- Aug 2026
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$1.1MraisedJun 2017 · 21 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJun 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Wayne DavieExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- Proceeds to insiders
- $180K
- Placement agents
- James W Davie
- First sale
- Jan 2015
- Incorporated
- Corporation, Washington, 2012
- Federal exemptions
- 06b
▶$1MofferedNov 2015 · BiotechnologyRule 506(b)
▶$1MofferedNov 2015 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Wayne DavieExecutive Officer, Director
- Offering amount
- $1M
- Minimum investment
- $25K
- Proceeds to insiders
- $120K
- Incorporated
- Corporation, Washington, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $447.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does MalarVx do?
- A company focused on addressing malaria through research and solutions aimed at reducing the disease's health and economic burden.
- How much funding has MalarVx raised?
- MalarVx has disclosed $1.2M raised across 2 of its 3 known rounds.
- Where is MalarVx headquartered?
- MalarVx is headquartered in Seattle, US.